Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers.
The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL).
AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC).
AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.
Company Details
- Employees
- 76
- Founded
- -
- Address
- Gottlieb-Daimler Straße 2, Mannheim,bw 68165,germany
- Phone
- +49 (0)6221-6743-60
- in****@****med.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- affimed.com
- Keywords
- jobs.
- HQ
- Mannheim, BW
Affimed Questions
Affimed's helpline number is +49 (0)6221-6743-60
Affimed's website is affimed.com
Affimed's LinkedIn profile is https://de.linkedin.com/company/affimed-ag
Affimed has
76 employees.
View email and phone details for 76
employees at Affimed.
Affimed's industry is
Biotechnology Research
Affimed's top competitors are
Medigene Ag,
Curevac,
Heidelberg Pharma Research Gmbh,
Heidelberg Pharma Ag,
Veraxa Biotech,
Biolabs Heidelberg,
Immatics,
Biontech Se,
Molecular Health,
Biorn Life Science Cluster.
Affimed's support email address is info@affimed.com
Affimed's categories are Biotechnology Research
Affimed's founding year is 2000
